HENGRUI PHARMA: INTERIM RESULTS ANNOUNCEMENT FORTHE SIX MONTHS ENDED JUNE 30, 2025

In the first half of 2025, Hengrui Pharma achieved operating revenue of RMB 15.761 billion, a year-on-year increase of 15.9%; net profit attributable to shareholders was RMB 4.450 billion, a year-on-year increase of 29.7%. Revenue from innovative drug sales and licensing reached RMB 9.561 billion, accounting for 60.7% of total revenue, with innovative drug sales contributing RMB 7.570 billion. During the period, cumulative R&D investment amounted to RMB 3.871 billion, of which R&D expenditures were RMB 3.228 billion, reflecting a year-on-year increase of 6.3%. During the reporting period, the company received approvals for the market launch of six Class 1 innovative drugs, including injection of ricabate monotherapy, amivantamab tablets, and linagliptin metformin tablets; six new indications were also approved for market launch. The company...Show More

In the first half of 2025, Hengrui Pharma achieved operating revenue of RMB 15.761 billion, a year-on-year increase of 15.9%; net profit attributable to shareholders was RMB 4.450 billion, a year-on-year increase of 29.7%. Revenue from innovative drug sales and licensing reached RMB 9.561 billion, accounting for 60.7% of total revenue, with innovative drug sales contributing RMB 7.570 billion. During the period, cumulative R&D investment amounted to RMB 3.871 billion, of which R&D expenditures were RMB 3.228 billion, reflecting a year-on-year increase of 6.3%. During the reporting period, the company received approvals for the market launch of six Class 1 innovative drugs, including injection of ricabate monotherapy, amivantamab tablets, and linagliptin metformin tablets; six new indications were also approved for market launch. The company entered into an agreement with Merck Sharp & Dohme, receiving an upfront payment of USD 200 million, and reached an agreement with IDEAYA Biosciences for an upfront payment of USD 75 million, making licensing of innovative drugs an important component of revenue. The company continues to increase its R&D investment, with 15 independently developed innovative molecules entering clinical stages for the first time during the reporting period, covering multiple therapeutic areas including oncology, metabolic and cardiovascular diseases, immunology, and respiratory diseases. The company's commercialization network now covers over 25,000 hospitals and more than 200,000 offline retail pharmacies across more than 30 provincial-level administrative regions in China, significantly enhancing its brand influence at the grassroots level.